Dr. Robert Tansley
Robert Tansley joined CIC in January 2014 and heads up the healthcare investment team. After seven years working in hospital medicine, Robert joined the pharma industry in 1996 working in development and regulatory roles at Sanofi, the MHRA and Roche. Robert subsequently joined the Cambridge-based company Arakis and worked as Medical Director until its £106 million sale to Sosei Inc. Since that acquisition, he has been involved in a number of start-up companies, including founding the malaria-focused company Treague and being founding CEO of the University of Copenhagen spin-out Avilex Pharma. In addition, he was part of the founding management team of KalVista which is developing the first plasma kallikrein inhibitor for diabetic macular edema working with its scientific founders from Harvard Medical School. His portfolio includes Congenica, Inivata, Cambridge Medical Robotics, Abcodia, Storm Therapeutics and Morphogen-IX. Robert qualified in medicine from University College London. He is a member of the Royal College of Obstetricians & Gynaecologists and the Faculty of Pharmaceutical Medicine and has an MBA from London Business School and an M.Phil in Biostatistics from the University of Cambridge.